Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215746 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9945539 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9964306 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1582511 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9964305 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL705500 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25400489 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16572007 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12170354 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17972429 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721764-A1 | DSRNA TARGETING LPA AND USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2025038971-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4405368-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES FOR USE IN THE IN-VIVO DELIVERY OF OLIGONUCLEOTIDES | Sanegene Bio USA Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230183746-A1 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2023-06-15 | — | — | US | disclosed |
| WO-2023049258-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES FOR USE IN THE IN-VIVO DELIVERY OF OLIGONUCLEOTIDES | SANEGENE BIO USA INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-5872232-A | 2'-O-modified oligonucleotides | ISIS PHARMACEUTICALS INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5866700-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-02 | — | — | US | disclosed |
| US-5859221-A | HYBRID DNA, RNA; NUCLEASE RESISTANT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5808035-A | OLIGOMER BIOSYNTHESIS | USHER, DAVID A. | 1998-09-15 | — | — | US | disclosed |
| US-5652358-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | disclosed |
| US-5639647-A | USEFUL IN ENZYMETIC CLEAVAGE OF RNA OR SINGLE STRANDED DNA, AND ALSO AS ANTISENSE OLIGONUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5627053-A | STABILIZATION OF OLIGONUCLEOTIDES, ANTISENSE MOLECULES AND FORMING ALLYL DERIVATIVES FROM TRITYL-SILYL DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0746614-A1 | METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023225-A2 | METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | NSUN2, NSUN3, ADAR | SLC28A1 988/4885SLC28A2 719/4885SLC29A1 933/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC28A1 59/4885SLC28A2 84/4885SLC29A1 36/4885 |
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | PARP1, PARP2, CD38 | SLC28A1 230/4885SLC28A2 149/4885SLC29A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.